Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.
MetadataShow full item record
AbstractThe development of potent antiretroviral drugs has significantly reduced morbidity and mortality associated with human immunodeficiency virus infection, however, the effectiveness of these medications depends upon consistent daily oral intake. Non-adherence can lead to the emergence of resistance, treatment failure and disease progression. This has necessitated the development of long-acting antiretroviral formulations administrable via an infrequent dosing regimen. Long-acting injectable forms of cabotegravir and rilpivirine have reached various stages in clinical trials both for the treatment and prevention of HIV. Other long-acting agents are at various stages of development. This review evaluates the current research on the development of long-acting injectable antiretroviral agents for the treatment and prevention of HIV. [Abstract copyright: Copyright © 2021 Elsevier B.V. All rights reserved.]
CitationJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology, volume 146, page 105032
DescriptionFrom PubMed via Jisc Publications Router
History: received 2021-05-18, revised 2021-10-06, accepted 2021-11-21
Publication status: aheadofprint